Profitability Metrics

Gross Margin
97.72%
Operating Margin
67.51%
Net Margin
53.03%

Efficiency Metrics

Revenue per Expense Ratio
3.08
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
97.90%
Income Tax Rate
0.33%
EPS
1.2500000000

Balance Sheet Analysis

Current Ratio
4.73
Cash Ratio
0.51
Working Capital
$292.78M
Debt to Equity
0.57
Debt to Assets
35.46%
Equity Ratio
62.47%

Cash Flow Analysis

Operating Cash Flow Ratio
70.79%
Free Cash Flow Ratio
-177.97%
CapEx to Revenue
248.77%
Dividends Paid
$168.23M
Stock Buybacks
$3.67M
Total Shareholder Returns
$171.90M
Cash Position Change
-31.52%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased dividend payments by 5.31%

Detailed Growth Metrics

Core Performance

Revenue
25.51%
Net Income
42.18%
EPS
26.26%
Operating Income
38.38%

Operational Efficiency

R&D Expenses
-100.00%
SG&A Expenses
4.12%
Operating Cash Flow
20.64%
Free Cash Flow
149.17%

Balance Sheet Health

Assets
19.21%
Debt
19.02%
Book Value per Share
6.11%
Inventory
-100.00%

Shareholder Returns

Dividends per Share
5.31%
Shares Outstanding
12.75%

Long Term Trends

3Y Revenue/Share
37.35%
5Y Revenue/Share
4.73%
3Y Dividend/Share
21.87%
5Y Dividend/Share
235.11%